IceCure Medical 股东特别大会复会并通过议程事项
6-K - IceCure Medical Ltd. (0001584371) (Filer)
IceCure Medical Ltd. 于 11 月 2 日召开年度及特别股东大会,因最初未达到法定人数而延期;复会时达到法定人数,股东随后批准了委托书中列明的议程事项。公司将这份 Form 6-K 纳入其已向 SEC 提交的 Form F-3 和 Form S-8 注册声明。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-40753
ICECURE MEDICAL LTD.
(Translation of registrant’s name into English)
7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On November 2, 2026, IceCure Medical Ltd. (the “Company”) convened its Annual and Special General Meeting of Shareholders (the “Meeting”).
The Meeting was initially adjourned due to there not being a required quorum present to open and conduct it at the initial time of 5:00 p.m. (Israel time). However, the adjourned Meeting was held at 6:30 p.m. (Israel time). At the adjourned Meeting, a quorum was present, and the shareholders of the Company voted upon and approved the agenda items that were described in the Company’s proxy statement for the Meeting, which were included in Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission (“SEC”) on October 5, 2026 (the “Proxy Statement”).
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-298361, 333-270982, 333-264578, 333-262620 and 333-281587), filed with the SEC, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IceCure Medical Ltd. | |||
| Date: November 2, 2026 | By: | /s/ Eyal Shamir | |
| Name: | Eyal Shamir | ||
| Title: | Chief Executive Officer | ||
2
来源:SEC EDGAR · 本站存档